Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Publication|Articles|February 19, 2025
- Ophthalmology Times: January/February 2025
- Volume 50
- Issue 1
Shaping the future of retinal therapy
Author(s) Arshad M. Khanani, MD, MA, FASRS
Fact checked by: Sheryl Stevenson
Advancements in drug durability and patient care are closing treatment gaps.
Advertisement
Advertisement
The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and improving clinicians’ ability to treat a variety of diseases. Even with this progress, significant gaps remain, especially regarding treatment durability.
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.
Advertisement
Advertisement